Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDEntero Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
Entero Therapeutics, Inc. Earnings Date And Information
Entero Therapeutics, Inc. last posted its earnings results on Monday, October 21st, 2024. The company reported $-3.37 earnings per share for the quarter, missing analysts' consensus estimates of $-0.32 by $3.05. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Entero Therapeutics, Inc. has generated $-48 earnings per share over the last year ($-47.88 diluted earnings per share) and currently has a price-to-earnings ratio of -0.23. Entero Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based on prior year's report dates.
Entero Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/30/2024 | Q3 2024 | -$1.55 | -$0.59 | 0.96 | $0 | $0 |
| 06/28/2024 | Q2 2024 | N/A | -$3.86 | N/A | $0 | $0 |
| 03/30/2024 | Q1 2024 | N/A | $3.12 | N/A | $0 | $0 |
| 12/30/2023 | Q4 2023 | N/A | -$2.68 | N/A | N/A | $0 |
| 09/29/2023 | Q3 2023 | N/A | -$9.21 | N/A | N/A | $0 |
| 06/29/2023 | Q2 2023 | N/A | -$37.73 | N/A | N/A | $0 |
| 03/30/2023 | Q1 2023 | N/A | -$36.46 | N/A | N/A | $0 |
| 12/30/2022 | Q4 2022 | N/A | -$80.08 | N/A | N/A | $0 |
| 09/29/2022 | Q3 2022 | N/A | $370.13 | N/A | $-4,430 | $0 |
| 06/29/2022 | Q2 2022 | N/A | -$1,069.40 | N/A | N/A | $0 |
| 03/30/2022 | Q1 2022 | N/A | -$2,786.36 | N/A | $-7,000 | $0 |
| 12/30/2021 | Q4 2021 | N/A | -$3,191.50 | N/A | N/A | $0 |
| 09/29/2021 | Q3 2021 | N/A | -$13,720.00 | N/A | N/A | $0 |
| 06/29/2021 | Q2 2021 | N/A | -$6,843.48 | N/A | N/A | $0 |
| 03/30/2021 | Q1 2021 | N/A | -$22,750.00 | N/A | N/A | $0 |
| 12/30/2020 | Q4 2020 | N/A | -$26,281.00 | N/A | N/A | $0 |
| 09/29/2020 | Q3 2020 | N/A | -$19,836.00 | N/A | N/A | $0 |
| 06/29/2020 | Q2 2020 | N/A | -$7,039.62 | N/A | N/A | $0 |
| 03/30/2020 | Q1 2020 | N/A | -$8,201.76 | N/A | N/A | $0 |
| 12/30/2019 | Q4 2019 | N/A | -$2,008.44 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Entero Therapeutics, Inc. Earnings: FAQ's
Entero Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based offlast year's report dates.
The conference call for Entero Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Entero Therapeutics, Inc.'s latest earnings report can be read online.
Entero Therapeutics, Inc. (:ENTO) has a recorded net income of $-15,794,983.Entero Therapeutics, Inc. has generated $-47.88 earnings per share over the last four quarters.
Entero Therapeutics, Inc. (:ENTO) has a price-to-earnings ratio of -0.23 and price/earnings-to-growth ratio is -0.